Advertisement

Reactions Weekly

, Volume 1747, Issue 1, pp 122–122 | Cite as

Entecavir/Tenofovir-disoproxil-fumarate

Drug resistance and kidney dysfunction: 5 case reports
Case report
  • 20 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

An open label, multi-centre retrospective study of 103 patients, who were switched from tenofovir to entecavir between March 2008−October 2015 due to kidney dysfunction, described four men and a woman (aged 58−71 years), who developed kidney dysfunction during treatment with tenofovir disoproxil fumarate, and further developed resistance to entecavir while being treated for hepatitis-B [routes and outcomes not stated; not all durations of treatments to reactions onsets stated].

A 67-year-old man, who had chronic hepatitis-B infection, and who was resistant to lamivudine, had been receiving tenofovir disoproxil fumarate at 245 mg/72hrs. He subsequently developed kidney dysfunction, which was suspected to be drug-induced. Therefore, his antiviral therapy was switched to entecavir....

Reference

  1. Vigano M, et al. Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. Liver International 39: 484-493, No. 3, Mar 2019. Available from: URL: http://doi.org/10.1111/liv.14017 - Italy

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations